• Study demonstrated safety and tolerability of H-Guard® to address serious immune system-driven complications of dialysis
• Encouraging biomarker data positions H-Guard® for upcoming Acute Kidney Injury trial

GLASGOW, Scotland, May 23, 2024 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, announces that eight patients have been successfully treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with H-Guard® Priming Solution in its first-in-human Phase 1 clinical study.

The study was conducted at the NIHR Manchester CRF at the Manchester Royal Infirmary (MRI), part of the Manchester University NHS Foundation Trust, led by Professor Sandip Mitra and co-investigators, Dr Leonard Ebah and Dr Duha Ilyas.

The study investigated the safety of H-Guard® in patients undergoing haemodialysis who are vulnerable to dialysis-induced immune activation. H-Guard® is flushed through the dialysis machine, coating all blood exposed surfaces prior to treatment.

Patients received a single treatment of H-Guard® with pre and post treatment evaluations demonstrating its safety and tolerability.

The next stage is the Phase2b study for Acute Kidney Injury (AKI) where the Continuous Renal Replacement Therapy (CRRT) filter in an Intensive Care Unit (ICU) is coated with H-Guard®.

Dr Magnus Nicolson, CEO of Invizius, said: "It has been a pleasure to work with Professor Mitra and his team to demonstrate the safety of H-Guard® on dialysis patients. This is an important milestone for H-Guard® and Invizius, allowing us to progress into a larger efficacy study showing the clinical benefits of controlling complement activation in CRRT and a number of extracorporeal systems."

Professor Sandip Mitra, Consultant Nephrologist and Professor of Renal Medicine at Manchester University NHS Foundation Trust, commented: "As our aim is to improve the outcomes of patients on dialysis, we are very encouraged by the results of the H-Guard® trial. This week at the ERA in Stockholm, Dr Ilyas Duha will be presenting data from Invizius sponsored trial CompAct-HD. This is the largest kinetic analysis of complement activation in routine haemodialysis (HD) ever undertaken in UK. Our results indicate patient specific complement activation associated with inflammatory response during routine haemodialysis. Reduction in complement activation in HD may yield significant clinical outcome benefits."

H-Guard® is a potent anti-inflammatory and anti-coagulatory, second generation, complement regulator which coats the dialysis filter and tubing during the priming process.

Invizius managed the trial with TCRSolutions.

Photo: https://mma.prnewswire.com/media/2419462/Invizius_H_Guard.jpg

Media enquiries:
Lorna Gardner Media House 
lorna@mediahouse.co.uk
+44 (0)7813 193618

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/inviziuss-pioneering-dialysis-product-h-guard-completes-first-in-human-clinical-study-302152886.html